|
1
|
Ferlay JSI, Ervik M, Dikshit R, Eser S,
Mathers C, Rebelo M, Parkin DM, Forman D and Bray F:
Incidence/mortality data. GLOBOCAN 2012 1.0. 2012, https://www.iarc.fr.
|
|
2
|
Pitti RM, Marsters SA, Ruppert S, Donahue
CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2
ligand, a new member of the tumor necrosis factor cytokine family.
J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang L and Fang B: Mechanisms of
resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther.
12:228–237. 2005. View Article : Google Scholar
|
|
4
|
Wiley SR, Schooley K, Smolak PJ, Din WS,
Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA,
et al: Identification and characterization of a new member of the
TNF family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kruyt FA: TRAIL and cancer therapy. Cancer
Lett. 263:14–25. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moody CA and Laimins LA: Human
papillomavirus oncoproteins: Pathways to transformation. Nat Rev
Cancer. 10:550–560. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hougardy BM, Maduro JH, van der Zee AG, de
Groot DJ, van den Heuvel FA, de Vries EG and de Jong S: Proteasome
inhibitor MG132 sensitizes HPV-positive human cervical cancer cells
to rhTRAIL-induced apoptosis. Int J Cancer. 118:1892–1900. 2006.
View Article : Google Scholar
|
|
8
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Akira S: Roles of STAT3 defined by
tissue-specific gene targeting. Oncogene. 19:2607–2611. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Levy DE and Lee CK: What does Stat3 do? J
Clin Invest. 109:1143–1148. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dudley AC, Thomas D, Best J and Jenkins A:
The STATs in cell stress-type responses. Cell Commun Signal.
2:82004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramírez de Arellano A, Lopez-Pulido EI,
Martínez-Neri PA, Estrada Chávez C, González Lucano R,
Fafutis-Morris M, Aguilar-Lemarroy A, Muñoz-Valle JF and
Pereira-Suárez AL: STAT3 activation is required for the
antiapoptotic effects of prolactin in cervical cancer cells. Cancer
Cell Int. 15:832015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Banerjee K and Resat H: Constitutive
activation of STAT3 in breast cancer cells: A review. Int J Cancer.
138:2570–2578. 2016. View Article : Google Scholar
|
|
15
|
Benekli M, Xia Z, Donohue KA, Ford LA,
Pixley LA, Baer MR, Baumann H and Wetzler M: Constitutive activity
of signal transducer and activator of transcription 3 protein in
acute myeloid leukemia blasts is associated with short disease-free
survival. Blood. 99:252–257. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takemoto S, Ushijima K, Kawano K,
Yamaguchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Ijichi M,
Kakuma T, et al: Expression of activated signal transducer and
activator of transcription-3 predicts poor prognosis in cervical
squamous-cell carcinoma. Br J Cancer. 101:967–972. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schoppmann SF, Jesch B, Friedrich J,
Jomrich G, Maroske F and Birner P: Phosphorylation of signal
transducer and activator of transcription 3 (STAT3) correlates with
Her-2 status, carbonic anhydrase 9 expression and prognosis in
esophageal cancer. Clin Exp Metastasis. 29:615–624. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mali SB: Review of STAT3 (Signal
Transducers and Activators of Transcription) in head and neck
cancer. Oral Oncol. 51:565–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kusaba M, Nakao K, Goto T, Nishimura D,
Kawashimo H, Shibata H, Motoyoshi Y, Taura N, Ichikawa T, Hamasaki
K, et al: Abrogation of constitutive STAT3 activity sensitizes
human hepatoma cells to TRAIL-mediated apoptosis. J Hepatol.
47:546–555. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lanuti P, Bertagnolo V, Pierdomenico L,
Bascelli A, Santavenere E, Alinari L, Capitani S, Miscia S and
Marchisio M: Enhancement of TRAIL cytotoxicity by AG-490 in human
ALL cells is characterized by downregulation of cIAP-1 and cIAP-2
through inhibition of Jak2/Stat3. Cell Res. 19:1079–1089. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Singh TR, Shankar S and Srivastava RK:
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL
in breast carcinoma. Oncogene. 24:4609–4623. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fulda S: Histone deacetylase (HDAC)
inhibitors and regulation of TRAIL-induced apoptosis. Exp Cell Res.
318:1208–1212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Earel JK Jr, VanOosten RL and Griffith TS:
Histone deacetylase inhibitors modulate the sensitivity of tumor
necrosis factor-related apoptosis-inducing ligand-resistant bladder
tumor cells. Cancer Res. 66:499–507. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fandy TE, Shankar S, Ross DD, Sausville E
and Srivastava RK: Interactive effects of HDAC inhibitors and TRAIL
on apoptosis are associated with changes in mitochondrial functions
and expressions of cell cycle regulatory genes in multiple myeloma.
Neoplasia. 7:646–657. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gupta M, Han JJ, Stenson M, Wellik L and
Witzig TE: Regulation of STAT3 by histone deacetylase-3 in diffuse
large B-cell lymphoma: Implications for therapy. Leukemia.
26:1356–1364. 2012. View Article : Google Scholar
|
|
26
|
Ganapathy S, Chen Q, Singh KP, Shankar S
and Srivastava RK: Resveratrol enhances antitumor activity of TRAIL
in prostate cancer xenografts through activation of FOXO
transcription factor. PLoS One. 5:e156272010. View Article : Google Scholar
|
|
27
|
Taguchi A, Koga K, Kawana K, Makabe T, Sue
F, Miyashita M, Yoshida M, Urata Y, Izumi G, Tkamura M, et al:
Resveratrol enhances apoptosis in endometriotic stromal cells. Am J
Reprod Immunol. 75:486–492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Quoc Trung L, Espinoza JL, Takami A and
Nakao S: Resveratrol induces cell cycle arrest and apoptosis in
malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS One.
8:e551832013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kotha A, Sekharam M, Cilenti L, Siddiquee
K, Khaled A, Zervos AS, Carter B, Turkson J and Jove R: Resveratrol
inhibits Src and Stat3 signaling and induces the apoptosis of
malignant cells containing activated Stat3 protein. Mol Cancer
Ther. 5:621–629. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tameda M, Sugimoto K, Shiraki K, Inagaki
Y, Ogura S, Kasai C, Yoneda M, Okamoto R, Yamamoto N, Takei Y, et
al: Resveratrol sensitizes HepG2 cells to TRAIL-induced apoptosis.
Anticancer Drugs. 25:1028–1034. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bharti AC, Donato N and Aggarwal BB:
Curcumin (diferu-loylmethane) inhibits constitutive and
IL-6-inducible STAT3 phosphorylation in human multiple myeloma
cells. J Immunol. 171:3863–3871. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alexandrow MG, Song LJ, Altiok S, Gray J,
Haura EB and Kumar NB: Curcumin: A novel Stat3 pathway inhibitor
for chemoprevention of lung cancer. Eur J Cancer Prev. 21:407–412.
2012. View Article : Google Scholar :
|
|
33
|
Shankar S, Chen Q, Sarva K, Siddiqui I and
Srivastava RK: Curcumin enhances the apoptosis-inducing potential
of TRAIL in prostate cancer cells: Molecular mechanisms of
apoptosis, migration and angiogenesis. J Mol Signal. 2:102007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Park S, Cho DH, Andera L, Suh N and Kim I:
Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by
regulating apoptosis-related proteins. Mol Cell Biochem. 383:39–48.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Glienke W, Maute L, Wicht J and Bergmann
L: Curcumin inhibits constitutive STAT3 phosphorylation in human
pancreatic cancer cell lines and downregulation of survivin/BIRC5
gene expression. Cancer Invest. 28:166–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu H, Kortylewski M and Pardoll D:
Crosstalk between cancer and immune cells: Role of STAT3 in the
tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar
|
|
37
|
Zhang HF and Lai R: STAT3 in Cancer -
Friend or Foe? Cancers (Basel). 6:1408–1440. 2014. View Article : Google Scholar
|
|
38
|
Pensa S, Regis G, Boselli D, Novelli F and
Poli V: STAT1 and STAT3 in tumorigenesis: Two sides of the same
coin. Madame Curie Bioscience Database. Landes Bioscience; Austin,
TX: 2009
|
|
39
|
Pectasides D, Kamposioras K, Papaxoinis G
and Pectasides E: Chemotherapy for recurrent cervical cancer.
Cancer Treat Rev. 34:603–613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Siddiquee K, Zhang S, Guida WC, Blaskovich
MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence
NJ, et al: Selective chemical probe inhibitor of Stat3, identified
through structure-based virtual screening, induces antitumor
activity. Proc Natl Acad Sci USA. 104:7391–7396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kimura K, Yamada T, Matsumoto M, Kido Y,
Hosooka T, Asahara S, Matsuda T, Ota T, Watanabe H, Sai Y, et al:
Endoplasmic reticulum stress inhibits STAT3-dependent suppression
of hepatic gluconeogenesis via dephosphorylation and deacetylation.
Diabetes. 61:61–73. 2012. View Article : Google Scholar :
|
|
42
|
Yang Z, Liu Y, Liao J, Gong C, Sun C, Zhou
X, Wei X, Zhang T, Gao Q, Ma D, et al: Quercetin induces
endoplasmic reticulum stress to enhance cDDP cytotoxicity in
ovarian cancer: Involvement of STAT3 signaling. FEBS J.
282:1111–1125. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Oyadomari S and Mori M: Roles of
CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ.
11:381–389. 2004. View Article : Google Scholar
|
|
44
|
Shukla S, Mahata S, Shishodia G, Pandey A,
Tyagi A, Vishnoi K, Basir SF, Das BC and Bharti AC: Functional
regulatory role of STAT3 in HPV16-mediated cervical carcinogenesis.
PLoS One. 8:e678492013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hetz C: The unfolded protein response:
Controlling cell fate decisions under ER stress and beyond. Nat Rev
Mol Cell Biol. 13:89–102. 2012.PubMed/NCBI
|
|
46
|
Jiang CC, Chen LH, Gillespie S, Kiejda KA,
Mhaidat N, Wang YF, Thorne R, Zhang XD and Hersey P: Tunicamycin
sensitizes human melanoma cells to tumor necrosis factor-related
apoptosis-inducing ligand-induced apoptosis by up-regulation of
TRAIL-R2 via the unfolded protein response. Cancer Res.
67:5880–5888. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jung YH, Lim EJ, Heo J, Kwon TK and Kim
YH: Tunicamycin sensitizes human prostate cells to TRAIL-induced
apoptosis by upregulation of TRAIL receptors and downregulation of
cIAP2. Int J Oncol. 40:1941–1948. 2012.PubMed/NCBI
|
|
48
|
Hasegawa A, Osuga Y, Hirota Y, Hamasaki K,
Kodama A, Harada M, Tajima T, Takemura Y, Hirata T, Yoshino O, et
al: Tunicamycin enhances the apoptosis induced by tumor necrosis
factor-related apoptosis-inducing ligand in endometriotic stromal
cells. Hum Reprod. 24:408–414. 2009. View Article : Google Scholar
|
|
49
|
Shiraishi T, Yoshida T, Nakata S, Horinaka
M, Wakada M, Mizutani Y, Miki T and Sakai T: Tunicamycin enhances
tumor necrosis factor-related apoptosis-inducing ligand-induced
apoptosis in human prostate cancer cells. Cancer Res. 65:6364–6370.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hu Y, Hong Y, Xu Y, Liu P, Guo DH and Chen
Y: Inhibition of the JAK/STAT pathway with ruxolitinib overcomes
cisplatin resistance in non-small-cell lung cancer NSCLC.
Apoptosis. 19:1627–1636. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Selvendiran K, Bratasz A, Kuppusamy ML,
Tazi MF, Rivera BK and Kuppusamy P: Hypoxia induces chemoresistance
in ovarian cancer cells by activation of signal transducer and
activator of transcription 3. Int J Cancer. 125:2198–2204. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
